Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | GAA | P10253 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.71 |
| ▸ | MEN1 | O00255 | 7/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.71 |
| ▸ | HPGD | P15428 | 5/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.71 |
| ▸ | BPTF | Q12830 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643671 | 0.84 | MAPT (0.73) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL13366491 | 0.83 | BPTF (0.72) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL3421133 | 0.83 | BPTF (1.00) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL2960524 | 0.82 | BPTF (0.70) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL4035961 | 0.82 | BPTF (0.78) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL2960241 | 0.81 | BPTF (0.72) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL2963988 | 0.80 | MAPT (0.67) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL8288691 | 0.80 | ADORA1 (0.68) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL970355 | 0.80 | ADORA1 (0.83) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL2969418 | 0.79 | BPTF (0.69) | MAPTGAAKDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2010-12-23 | — | — | US | disclosed |
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2010-12-23 | — | — | US | disclosed |
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2010-12-23 | — | — | US | disclosed |
| US-7803945-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7803945-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7803945-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7741488-B2 | Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer | 4SC AG (DE) | 2010-06-22 | — | — | US | disclosed |
| US-7741488-B2 | Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer | 4SC AG (DE) | 2010-06-22 | — | — | US | disclosed |
| US-7741488-B2 | Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer | 4SC AG (DE) | 2010-06-22 | — | — | US | disclosed |
| US-7723523-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-25 | — | — | US | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| EP-1758655-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR TREATING HYPERPROLIFERATIVE DISORDERS | Altana Pharma AG (DE) | 2007-03-07 | — | — | EP | disclosed |
| EP-1756118-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Altana Pharma AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1753512-A2 | TETRAHYDROPYRIDOTHIOPHENES | Altana Pharma AG (DE) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006084904-A1 | TETRAHYDROPYRIDOTHIOPHENES AS ANTRIPOLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006084869-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | NYCOMED GMBH (DE) | 2006-08-17 | — | — | WO | disclosed |
| WO-2005120642-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR TREATING HYPERPROLIFERATIVE DISORDERS | ALTANA PHARMA AG (DE) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005118592-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | ALTANA PHARMA AG (DE) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118071-A2 | TETRAHYDROPYRIDOTHIOPHENES | ALTANA PHARMA AG (DE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | CCNT1, MALT1, CCNA1 | MAPT 3705/4885GAA 3288/4885KDM4E 2362/4885 |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | BCL2, BAX, MCL1 | MAPT 1402/4885GAA 3762/4885KDM4E 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.